|
| The clinical observation of Jinlida granule as Add-On metformin treat the newly diagnosed type 2 diabetic patients |
| Hits 1515 Download times 1536 Received:June 04, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2017.05.08 |
| Key Words
newly diagnosed type 2 diabetes;treatment determination from spleen;Jinlida granule;metformin |
| Author Name | Affiliation | E-mail | | ZHAO Jin-dong | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | LI Yan | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | LIU Shi-fu | Wuhu Hospital of Chinese Medicine, Wuhu 241000, China | | | CAO Hui-bo | Chuzhou Hospital of Chinese Medicine and Western medicine, Chuzhou 239000, China | | | PEI Guo-yong | Huangshan Hospital of Chinese Medicine, Huangshan 242700, China | | | HA Tuan-jie | Taihe Hospital of Chinese Medicine, Taihe 236600, China | | | WANG Xiao-hong | Ningguo Hospital of Chinese Medicine, Ningguo 242300, China | | | LU Ping | Lixin Hospital of Chinese Medicine, Lixin 236700, China | | | BI Dao-yin | Changfeng Hospital of Chinese Medicine, Changfeng 231100, China | | | NIU Yun-fei | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | SHU Yi-qiong | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | DING Lei | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | NI Ying-qun | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | LU Rui-min | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | LI Jia-yun | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | | | FANG Zhao-hui | The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China | fangzhaohui1111@163.com |
|
| Abstract
|
| [Objective] To observe the safety and efficacy of Jinlida granule combined with metformin in the treatment of newly diagnosed type 2 diabetes mellitus.[Methods] A total of 156 newly diagnosed type 2 diabetic patients were enrolled in the study. All of the patients on the basis of metformin to conventional treatment, were randomly assigned to take Jinlida granule(treatment group) or placebo (control group). The end of the study was followed by the 12th week of subject Glycated HemoglobinA1c(HbA1c), Fasting plasma glucose(FPG), 2 h postprandial glucose(2 h PG).[Results] At 12 weeks of follow-up, the treatment group HbA1c was (6.61±0.63)%, the placebo group HbA1c was (6.91±1.09)%. The difference was statistically significant(P<0.05). The FPG of the treatment group was (7.31±1.12) mmol/L. The placebo group FPG was (7.63±0.77). The 2 h PG of the treatment group was (10.63±1.80) mmol/L. The placebo group 2 h PG was (11.46±2.42) mmol/L. The difference was statistically significant(P<0.05). The treatment group success rate was 83.3%, the control group is 67.9%. The effective rate of Chinese Medicine(CM) syndromes was 85.8% in the treatment group and 57.7% in the control group, the difference was statistically significant (P<0.05). Two groups of treatment group were not serious adverse events related to study drug.[Conclusion] The results showed that on the basis of metformin treatment, combination of Jinlida granule can make the patients with newly diagnosed type 2 diabetes better control of blood sugar level. Applied in newly diagnosed type 2 diabetes is safe and effective. |
|
|
|
|
|
